MediWound to present financial results for the first quarter of 2024

MediWound Ltda.

Conference call and webcast scheduled for Wednesday, May 29 at 8:30 a.m. ET

YAVNE, Israel, May 22, 2024 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzyme therapeutics for tissue repair, today announced that the company will release its financial results for the first quarter ended on March 31, 2024 on Wednesday, May 29, 2024.

Following the launch, management will host a conference call and live webcast at 8:30 a.m. ET to discuss financial results, provide corporate updates and answer questions.

Dialing and calling details are as follows:

To access the call, participants must dial the number applicable telephone number above at least 5 minutes before the start of the call. An archived version of the webcast will be available for replay in the Investors section of the MediWound website.

About MediWound

(Nasdaq: MDWD) is a global leader in next-generation enzyme therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of rapid and effective biologics that improve existing standards of care and patient experiences while reducing costs and unnecessary surgeries.

MediWound’s first medicine, NexoBrid®, is an orphan biologic medicine approved by the FDA and EMA for the removal of bedsores in partial and/or full thickness deep thermal burns, which can significantly reduce surgical interventions. Utilizing the same core biotherapeutic enzyme platform technology, MediWound has developed a strong R&D pipeline, including the company’s lead drug in development, EscharEx®. EscharEx is a Phase III-ready biologic for chronic wound debridement, offering significant potential advantages over the dominant $360+ million product and an opportunity to expand the market.

For more information visit www.mediwound.com and follow the company on LinkedIn.

Source